Qube Research & Technologies (QRT)
IBRX icon

Qube Research & Technologies (QRT)’s ImmunityBio IBRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24,796
Closed -$45.1K – 2663
2023
Q1 		$45.1K Sell
24,796
-25,826
-51% -$80.3K ﹤0.01% 2235
2022
Q4 		$257K Buy
+50,622
New +$278K ﹤0.01% 1708
2022
Q3 		– Sell
-135,655
Closed -$505K – 2726
2022
Q2 		$505K Buy
135,655
+83,890
+162% +$337K ﹤0.01% 1403
2022
Q1 		$290K Sell
51,765
-39,749
-43% -$244K ﹤0.01% 1801
2021
Q4 		$556K Buy
+91,514
New +$688K ﹤0.01% 1508
2021
Q2 		– Sell
-31,444
Closed -$746K – 2504
2021
Q1 		$746K Buy
+31,444
New +$815K 0.01% 969
2020
Q4 		– Sell
-55,479
Closed -$385K – 1981
2020
Q3 		$385K Buy
+55,479
New +$553K 0.01% 1134
2020
Q2 		– Sell
-44,334
Closed -$128K – 1840
2020
Q1 		$128K Sell
44,334
-94,767
-68% -$475K 0.01% 936
2019
Q4 		$527K Buy
+139,101
New +$237K 0.02% 922

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Qube Research & Technologies (QRT)'s IBRX Position: Q2 2023 in Review

Qube Research & Technologies (QRT) sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 24,796 shares — an estimated $45.1K sold.

Qube Research & Technologies (QRT) first reported a position in IBRX in Q4 2019 and held it in 9 quarters. The position peaked at $746K in Q1 2021. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

  • Qube Research & Technologies (QRT) reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 24,796 ImmunityBio shares in Q2 2023, an estimated $45.1K.
  • Qube Research & Technologies (QRT) first reported a position in ImmunityBio in Q4 2019 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s ImmunityBio position peaked at $746K in Q1 2021.
  • 117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2023, filed 14 Aug 2023.